Shilin District Court deny OBI’s request to submit the case for trial

OBI Pharma Inc. to attend the investor conference on new drug development, hosted by Masterlink Securities
January 5, 2018
FDA Clearance of IND Application for A Phase 1 Study of A Monoclonal Antibody Cancer Immunotherapy (OBI-888)
January 17, 2018
  1. Defendant: Reporter Pei amongst the other six reporters
  2. Name of the legal agency or court: Taiwan Shilin District Court
  3. Reference/case numbers of relevant documents: 2017 Sheng Pan Zi, No. 72
  4. Date of occurrence of the event: January 8, 2018
  5. Background and circumstances of the matter (including the property/subject matter under dispute): The company received Shilin District Court’s decision for the denial of OBI’s request to submit the case for trial.
  6. Course and progression of handling of the matter: The company will consult its legal counsel on appropriate legal responses.
  7. Effect on company finances and business and estimated monetary amount of the effect: The business operation and financial status of the company are normal.
  8. Countermeasures and status of amelioration: None
  9. Any other matters that need to be specified: N